CRITICAL · 9.8

CVE-2013-3323

A Privilege Escalation Vulnerability exists in IBM Maximo Asset Management 7.5, 7.1, and 6.2, when WebSeal with Basic Authentication is used, due to a failure to invalidate the authentication session,...

Vulnerability Description

A Privilege Escalation Vulnerability exists in IBM Maximo Asset Management 7.5, 7.1, and 6.2, when WebSeal with Basic Authentication is used, due to a failure to invalidate the authentication session, which could let a malicious user obtain unauthorized access.

CVSS Score

9.8

CRITICAL

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:H
Attack Vector
NETWORK
Attack Complexity
LOW
Privileges Required
NONE
User Interaction
NONE
Scope
UNCHANGED
Confidentiality
HIGH
Integrity
HIGH
Availability
HIGH

Affected Products

VendorProductVersions
IbmChange And Configuration Management Database7.1
IbmMaximo Asset Management6.2
IbmMaximo Asset Management Essentials6.2
IbmMaximo For Government6.2
IbmMaximo For Life Sciences6.2
IbmMaximo For Nuclear Power6.2
IbmMaximo For Oil And Gas6.2
IbmMaximo For Transportation6.2
IbmMaximo For Utilities6.2
IbmMaximo Service Desk6.2
IbmSmartcloud Control Desk7.5
IbmTivoli Asset Management For It6.2
IbmTivoli Service Request Manager7.1

Related Weaknesses (CWE)

References

FAQ

What is CVE-2013-3323?

CVE-2013-3323 is a vulnerability with a CVSS score of 9.8 (CRITICAL). A Privilege Escalation Vulnerability exists in IBM Maximo Asset Management 7.5, 7.1, and 6.2, when WebSeal with Basic Authentication is used, due to a failure to invalidate the authentication session,...

How severe is CVE-2013-3323?

CVE-2013-3323 has been rated CRITICAL with a CVSS base score of 9.8/10. This is considered a critical vulnerability requiring immediate attention.

Is there a patch for CVE-2013-3323?

Check the references section above for vendor advisories and patch information. Affected products include: Ibm Change And Configuration Management Database, Ibm Maximo Asset Management, Ibm Maximo Asset Management Essentials, Ibm Maximo For Government, Ibm Maximo For Life Sciences.